Literature DB >> 29476037

Attention-deficit/hyperactivity disorder medication and seizures.

Kelsey K Wiggs1, Zheng Chang2, Patrick D Quinn2, Kwan Hur2, Robert Gibbons2, David Dunn2, Isabell Brikell2, Henrik Larsson2, Brian M D'Onofrio2.   

Abstract

OBJECTIVE: Individuals with attention-deficit/hyperactivity disorder (ADHD) are at increased risk of seizures, but there is uncertainty about whether ADHD medication treatment increases risk among patients with and without preexisting seizures.
METHODS: We followed a sample of 801,838 patients with ADHD who had prescribed drug claims from the Truven Health MarketScan Commercial Claims and Encounters databases to examine whether ADHD medication increases the likelihood of seizures among ADHD patients with and without a history of seizures. First, we assessed overall risk of seizures among patients with ADHD. Second, within-individual concurrent analyses assessed odds of seizure events during months when a patient with ADHD received ADHD medication compared with when the same individual did not, while adjusting for antiepileptic medications. Third, within-individual long-term analyses examined odds of seizure events in relation to the duration of months over the previous 2 years patients received medication.
RESULTS: Patients with ADHD were at higher odds for any seizure compared with non-ADHD controls (odds ratio [OR] = 2.33, 95% confidence interval [CI] = 2.24-2.42 males; OR = 2.31, 95% CI = 2.22-2.42 females). In adjusted within-individual comparisons, ADHD medication was associated with lower odds of seizures among patients with (OR = 0.71, 95% CI = 0.60-0.85) and without (OR = 0.71, 95% CI = 0.62-0.82) prior seizures. Long-term within-individual comparisons suggested no evidence of an association between medication use and seizures among individuals with (OR = 0.87, 95% CI = 0.59-1.30) and without (OR = 1.01, 95% CI = 0.80-1.28) a seizure history.
CONCLUSIONS: Results reaffirm that patients with ADHD are at higher risk of seizures. However, ADHD medication was associated with lower risk of seizures within individuals while they were dispensed medication, which is not consistent with the hypothesis that ADHD medication increases risk of seizures.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 29476037      PMCID: PMC5880635          DOI: 10.1212/WNL.0000000000005213

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

1.  Stimulant therapy and seizure risk in children with ADHD.

Authors:  S A Hemmer; J F Pasternak; S G Zecker; B L Trommer
Journal:  Pediatr Neurol       Date:  2001-02       Impact factor: 3.372

2.  Stimulant ADHD medication and risk for substance abuse.

Authors:  Zheng Chang; Paul Lichtenstein; Linda Halldner; Brian D'Onofrio; Eva Serlachius; Seena Fazel; Niklas Långström; Henrik Larsson
Journal:  J Child Psychol Psychiatry       Date:  2013-10-25       Impact factor: 8.982

3.  Quantifying the Benefits and Risks of Methylphenidate as Treatment for Childhood Attention-Deficit/Hyperactivity Disorder.

Authors:  Philip Shaw
Journal:  JAMA       Date:  2016-05-10       Impact factor: 56.272

4.  ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate.

Authors:  Sylvain Rheims; Vania Herbillon; Nathalie Villeneuve; Stéphane Auvin; Silvia Napuri; Claude Cances; Patrick Berquin; Pierre Castelneau; Sylvie Nguyen The Tich; Frédéric Villega; Hervé Isnard; Rima Nabbout; Ségolène Gaillard; Catherine Mercier; Behrouz Kassai; Alexis Arzimanoglou
Journal:  Epilepsia       Date:  2016-05-29       Impact factor: 5.864

5.  ADHD Medication and Substance-Related Problems.

Authors:  Patrick D Quinn; Zheng Chang; Kwan Hur; Robert D Gibbons; Benjamin B Lahey; Martin E Rickert; Arvid Sjölander; Paul Lichtenstein; Henrik Larsson; Brian M D'Onofrio
Journal:  Am J Psychiatry       Date:  2017-06-29       Impact factor: 18.112

6.  ADHD, neurological correlates and health-related quality of life in severe pediatric epilepsy.

Authors:  Elisabeth M S Sherman; Daniel J Slick; Mary B Connolly; Kim L Eyrl
Journal:  Epilepsia       Date:  2007-03-22       Impact factor: 5.864

7.  Premorbid prevalence of ADHD and development of secondary ADHD after closed head injury.

Authors:  J P Gerring; K D Brady; A Chen; R Vasa; M Grados; K J Bandeen-Roche; R N Bryan; M B Denckla
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1998-06       Impact factor: 8.829

8.  ADHD and epilepsy in childhood.

Authors:  David W Dunn; Joan K Austin; Jaroslaw Harezlak; Walter T Ambrosius
Journal:  Dev Med Child Neurol       Date:  2003-01       Impact factor: 5.449

9.  Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study.

Authors:  Zheng Chang; Paul Lichtenstein; Brian M D'Onofrio; Arvid Sjölander; Henrik Larsson
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

10.  Methylphenidate, cognition, and epilepsy: A double-blind, placebo-controlled, single-dose study.

Authors:  Jesse Adams; Valerie Alipio-Jocson; Katherine Inoyama; Victoria Bartlett; Saira Sandhu; Jemima Oso; John J Barry; David W Loring; Kimford Meador
Journal:  Neurology       Date:  2016-12-28       Impact factor: 9.910

View more
  9 in total

Review 1.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

2.  The association between early childhood onset epilepsy and attention-deficit hyperactivity disorder (ADHD) in 3237 children and adolescents with Autism Spectrum Disorder (ASD): a historical longitudinal cohort data linkage study.

Authors:  Vibhore Prasad; Johnny Downs; Lauren Carson; Valeria Parlatini; Tara Safa; Benjamin Baig; Hitesh Shetty; Jacqueline Phillips-Owen
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-08-04       Impact factor: 5.349

3.  Depression and Suicidal Behavior in Young Adult Men and Women With ADHD: Evidence From Claims Data.

Authors:  Dara E Babinski; Kristina A Neely; Djibril M Ba; Guodong Liu
Journal:  J Clin Psychiatry       Date:  2020-09-22       Impact factor: 4.384

4.  Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy.

Authors:  Isabell Brikell; Qi Chen; Ralf Kuja-Halkola; Brian M D'Onofrio; Kelsey K Wiggs; Paul Lichtenstein; Catarina Almqvist; Patrick D Quinn; Zheng Chang; Henrik Larsson
Journal:  Epilepsia       Date:  2019-01-25       Impact factor: 5.864

Review 5.  Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-11-24       Impact factor: 3.022

6.  Protective Effect of Escitalopram on Hepatocellular Carcinoma by Inducing Autophagy.

Authors:  Li-Jeng Chen; Tsai-Ching Hsu; Hsiang-Lin Chan; Chiao-Fan Lin; Jing-Yu Huang; Robert Stewart; Bor-Show Tzang; Vincent Chin-Hung Chen
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

7.  Mainstreaming adult ADHD into primary care in the UK: guidance, practice, and best practice recommendations.

Authors:  Philip Asherson; Laurence Leaver; Marios Adamou; Muhammad Arif; Gemma Askey; Margi Butler; Sally Cubbin; Tamsin Newlove-Delgado; James Kustow; Jonathan Lanham-Cook; James Findlay; Judith Maxwell; Peter Mason; Helen Read; Kobus van Rensburg; Ulrich Müller-Sedgwick; Jane Sedgwick-Müller; Caroline Skirrow
Journal:  BMC Psychiatry       Date:  2022-10-11       Impact factor: 4.144

Review 8.  Do Psychotropic Drugs Cause Epileptic Seizures? A Review of the Available Evidence.

Authors:  Kamil Detyniecki
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 9.  Methylphenidate for attention problems in epilepsy patients: Safety and efficacy.

Authors:  Beth A Leeman-Markowski; Jesse Adams; Samantha P Martin; Orrin Devinsky; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2020-12-24       Impact factor: 2.937

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.